29O - Proffered Paper session 1

Date 25 February 2019
Event ESMO Targeted Anticancer Therapies Congress 2019
Session Proffered Paper session : Immunotherapy
Topics Cancers in Adolescents and Young Adults (AYA)
Presenter Teresa de Rojas
Citation Annals of Oncology (2019) 30 (suppl_1): i12-i14. 10.1093/annonc/mdz026
Authors T. de Rojas1, A. Neven2, M. Garcia-Abos3, L. Moreno4, N. Gaspar5, J. Peron1
  • 1Medical Department, EORTC - European Organisation for Research and Treatment of Cancer, 1200 - Brussels/BE
  • 2Statistics Department, EORTC - European Organisation for Research and Treatment of Cancer, 1200 - Brussels/BE
  • 3Pediatric Oncology, Hospital Donostia, San Sebastian/ES
  • 4Clinical Research Unit, Hospital Niño Jesús, Madrid/ES
  • 5Oncology For Child And Adolescent, Gustave Roussy Cancer Campus, Villejuif/FR

Abstract

The 18-years-old age limit for inclusion in clinical trials constitutes a major hurdle for adolescents and young adults (AYAs) with cancer that the main stakeholders are advocating to overthrow. The purpose of this study was 1) to analyze the access for adolescents with cancer to targeted therapies and immunotherapies and to innovation (measured in number of mechanisms of action –MoA-), when compared to young adults; and 2) to describe the time lapse between the first adult trial for a specific drug and the first trial recruiting adolescents for that same drug.